What this ETF is trying to do

The First Trust NYSE Arca Biotechnology Index Fund (FBT) is an ETF designed to track the biotechnology sector. It invests in companies involved in biotech research and development. This fund provides exposure to a variety of different biotechnology firms rather than just one single company.

What the numbers show

The data shows that FBT has experienced significant share-price growth over various timeframes.

• Year-to-Date (YTD): The price return is approximately 31.19%.

• One-Year: The price return is approximately 43.24%.

• Three-Year: The price return is approximately 84.81%.

When looking at total returns—which include the effect of distributions—the three-year total return is approximately 86.09%. For comparison, an estimated price from roughly one year ago was $189.14, while the current price is $270.93.

Income and distribution explanation

Based on the supplied facts, no distributions have been detected for this ETF. The distribution yield is 0%, and there has been no payout count over the last 12 months. Because there are no distributions, the price return and the total return figures provided in the data are the same.

NAV erosion explanation

"NAV erosion" refers to a decline in the Net Asset Value (the actual value of the assets held by the fund). While a falling share price can sometimes be a sign of erosion, it is not proof of it.

For FBT, the erosion-risk score is 100, which is labeled as "No price erosion detected." The erosion severity is described as "good," and there is no severe erosion-risk flag present.

Pros

• Strong Price Growth: The fund has shown high price returns over the one-year and three-year periods.

• Low Erosion Risk: The data indicates no detected price erosion.

Cons

• No Income: This ETF does not currently provide cash distributions or a dividend yield for investors seeking regular income.

Top Holdings

The following are the top holdings in the fund (note that this is a partial list):

• HALOZYME THERAPEUTICS INC (4.34%)

• NEOGENOMICS INC (3.94%)

• REPLIGEN CORP (3.90%)

• CORCEPT THERAPEUTICS INC (3.83%)

• BEONE MEDICINES LTD ADR (3.74%)

• REGENERON PHARMACEUTICALS INC (3.74%)

• NATERA INC (3.70%)

• AMGEN INC (3.67%)

• ARGENX SE ADR (3.65%)

• GENMAB AS ADR (3.55%)

Holdings can change over time. This data was updated as of October 7, 2026.

Beginner takeaway

FBT is a biotechnology-focused ETF that has seen strong share-price increases over the last year and three years. However, it is not an income-focused fund, as it currently shows no history of paying distributions.